Displaying drugs 11276 - 11300 of 11637 in total
BLX-883
BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. Alfa interferon is used in the treatment of hepatitis C, hepatitis B, and multiple cancers and its worldwide sales currently exceed $3 billion.
Investigational
Matched Description: … BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. …
Lortalamine
Lortalamine (LM-1404) is a selective norepinephrine reuptake inhibitor developed in the 1980s. This drug never made it past clinical trials, likely due to ocular toxicity in animals, but has been used in positron emission tomography studies to label norepinephrine transporters.
Experimental
Matched Description: … Lortalamine (LM-1404) is a selective norepinephrine reuptake inhibitor developed in the 1980s. …
Racivir
Racivir, also known as RCV, is an oxothiolane nucleoside reverse transcriptase inhibitor similar to emtricitabine and lamivudine. Racivir is a 50:50 mixture of emtricitabine and its positive enantiomer. Racivir has been used in trials studying the prevention of HIV Infections.
Investigational
Matched Description: … Racivir is a 50:50 mixture of [emtricitabine] and its positive enantiomer. …
SB 11285
SB 11285 is a second-generation Stimulator of Interferon Genes (STING) agonist. SB 11285 is under investigation in clinical trial NCT04096638 (Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors).
Investigational
Matched Description: … SB 11285 is a second-generation Stimulator of Interferon Genes (STING) agonist. …
Tandutinib
MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth. AML patients with FLT3 mutations...
Investigational
Matched Description: … Approximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. ... MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including …
Cefovecin
Cefovecin is a cephalosporin antibiotic used for the treatment of skin infections in cats and dogs. It is the first single-dose injectable antibiotic for dogs and cats that assures owner compliance with dosing for the animal. It is used for the treatment of skin infections caused by Pasturella multocida in...
Experimental
Vet approved
Matched Description: … Cefovecin is a cephalosporin antibiotic used for the treatment of skin infections in cats and dogs. ... The advantage of using injectable antibiotics is not missing a dose that can allow partially resistant …
IMM101
IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039]. Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help...
Investigational
Matched Description: … IMM-101 is a heat-inactivated immune-activating mycobacterial product. ... partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a …
FT516
FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation. FT516 is currently being tested against acute...
Investigational
Matched Description: … It is also a potential therapy for COVID-19. ... This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding …
Egaptivon pegol
Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute coronary syndromes.[A3290, A259053] Egaptivon pegol is a therapeutic...
Investigational
Matched Description: … Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von ... [A3290, A259053] Egaptivon pegol is a therapeutic oligonucleotide ("aptamer") which blocks the binding …
PH-284
PH-284 belongs to a new family of new chemical entities called vomeropherins. Vomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device so that they can bind to peripheral chemosensory receptors in the nasal passages. This binding produces neural impulses that are transmitted by specific...
Investigational
Matched Description: … PH-284 belongs to a new family of new chemical entities called vomeropherins. ... Vomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device …
DTS-201
DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment.
DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially...
Investigational
Matched Description: … DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for …
Synephrine
Synephrine, also referred to as, p-synephrine, is naturally occurring alkaloid. It is present in approved drug products as neo-synephrine, its m-substituted analog. p-synephrine and m-synephrine are known for their longer acting adrenergic effects compared to norepinephrine.
The similarity of naming between m-synephrine and the unsubstituted form, synephrine, is a source...
Experimental
Matched Description: … The similarity of naming between m-synephrine and the unsubstituted form, synephrine, is a source of ... some confusion however m-synephrine refers to a related drug more commonly known as phenylephrine. …
Virus Specific T-Cell
Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources. Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and...
Investigational
Matched Description: … Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. ... These T-cells are then isolated from the donor and expanded in a culture to generate more VSTs. …
Tilmicosin
Tilmicosin is a macrolide antibiotic. It is used in veterinary medicine for the treatment of bovine respiratory disease and ovine respiratory disease associated with Mannheimia haemolytica.
Investigational
Vet approved
Matched Description: … Tilmicosin is a macrolide antibiotic. …
Theanine
Theanine, a precursor of ethylamine, is found in green tea. It is under investigation in clinical trial NCT00291070 (Effects of L-Theanine in Boys With ADHD).
Investigational
Matched Description: … Theanine, a precursor of ethylamine, is found in green tea. …
Iboctadekin
Iboctadekin is under investigation in clinical trial NCT00500058 (A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18).
Investigational
Matched Description: … Iboctadekin is under investigation in clinical trial NCT00500058 (A Phase I, Dose-Escalation Study to …
PF-04634817
PF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects).
Investigational
Matched Description: … PF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine …
Ponezumab
Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).
Investigational
Matched Description: … Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 …
Vorsetuzumab mafodotin
Vorsetuzumab mafodotin is under investigation in clinical trial NCT01677390 (A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma).
Investigational
Matched Description: … Vorsetuzumab mafodotin is under investigation in clinical trial NCT01677390 (A Phase 1b Study of SGN- …
Pegbelfermin
Pegbelfermin is under investigation in clinical trial NCT03486899 (A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis).
Investigational
Matched Description: … Pegbelfermin is under investigation in clinical trial NCT03486899 (A Study of Experimental Medication …
HSK-3486
HSK-3486 is under investigation in clinical trial NCT04620031 (A Study Evaluating Sedation of Intravenous Administration of HSK3486 Injectable Emulsion in ICU Patients Undergoing Mechanical Ventilation).
Investigational
Matched Description: … HSK-3486 is under investigation in clinical trial NCT04620031 (A Study Evaluating Sedation of Intravenous …
Neihulizumab
Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells.
Investigational
Matched Description: … Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby …
MB-102 CD123 CAR
MB-102 are autologous T cells genetically modified to express CD123-specific, hinge-optimized CD28-costimulatory chimeric receptor and a truncated human epidermal growth factor receptor.
Investigational
Matched Description: … genetically modified to express CD123-specific, hinge-optimized CD28-costimulatory chimeric receptor and a …
Erfonrilimab
Erfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4).
Investigational
Matched Description: … Erfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand …
SLV319
SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor. It is developed for the treatment of obesity and other metabolic disorders.
Investigational
Matched Description: … SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid …
Displaying drugs 11276 - 11300 of 11637 in total